Use: Labeled indications
- Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ] .
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1)]. Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.
Glimepiride is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1). Limitations of Use: Not for treating type 1 diabetes mellitus or diabetic ketoacidosis (1).
Contraindications
- Hypersensitivity to glimepiride
- Allergy to sulfonamide derivatives
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: Glimepiride or any of the product’s ingredients [see Warnings and Precautions (5.2)]. Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets.
Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives. Hypersensitivity to glimepiride or any of the product's ingredients (4) Hypersensitivity to sulfonamide derivatives (4)
Dosing: Adult
- Type 2 diabetes: Start 1 or 2 mg once daily with breakfast; titrate by 1 to 2 mg every 1 to 2 weeks; maximum 8 mg/day
- Older adults, kidney impairment: Start 1 mg once daily; titrate slowly
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily. (2.1) Administer with breakfast or first meal of the day. (2.1) Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment).
(2.1) 2.1 Recommended Dosing Glimepiride tablets should be administered with breakfast or the first main meal of the day. The recommended starting dose of glimepiride tablets is 1 mg or 2 mg once daily. Patients at increased risk for hypoglycemia (e.g., the elderly or patients with renal impairment) should be started on 1 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5, 8.6)].
After reaching a daily dose of 2 mg, further dose increases can be made in increments of 1 mg or 2 mg based upon the patient’s glycemic response. Uptitration should not occur more frequently than every 1 to 2 weeks. A conservative titration scheme is recommended for patients at increased risk for hypoglycemia [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5, 8.6)].
The maximum recommended dose is 8 mg once daily. Patients being transferred to glimepiride tablets from longer half-life sulfonylureas (e.g., chlorpropamide) may have overlapping drug effect for 1 to 2 weeks and should be appropriately monitored for hypoglycemia. When colesevelam is coadministered with glimepiride, maximum plasma concentration and total exposure to glimepiride is reduced.
Therefore, glimepiride tablets should be administered at least 4 hours prior to colesevelam.
Dosing: Altered kidney function
Glimepiride is a sulfonylurea whose metabolites (M1, which has some glucose-lowering activity in animals, and M2) are excreted in urine and accumulate as kidney function falls. The US label starts all patients with kidney impairment at 1 mg once daily with slow titration because of hypoglycemia; it gives no CrCl cut-off and no dialysis dosing.
Kidney function measure: Label PK studies grouped creatinine clearance (CLcr >50, 20–50, <20 mL/min); dose advice is for 'renal impairment' without a number.
Show full dosing details
- CrCl ≥60 mL/min
- Start 1 or 2 mg once daily with breakfast; increase by 1 to 2 mg every 1 to 2 weeks; maximum 8 mg/day (label). Older adults: start 1 mg.
- CrCl 30–59 mL/min
- Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg.
- CrCl 15–29 mL/min
- Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg.
- CrCl <15 mL/min (not on dialysis)
- Start 1 mg once daily and titrate slowly (label 2.1, 8.6): hypoglycemia risk is higher in kidney impairment, and the M1 and M2 metabolites accumulate (M1 AUC 2.3-fold and M2 AUC 8.6-fold higher at CrCl <20). Studied at CrCl 10–60 mL/min with doses of 1 to 8 mg. No separate advice for CrCl <15; hypoglycemia can be prolonged. Specialist judgment.
- Hemodialysis (intermittent)
- Not studied in dialysis; the label gives no dialysis dose. Removal by hemodialysis unlikely (over 99.5% protein-bound). Specialist input; prefer agents with lower hypoglycemia risk.
- Peritoneal dialysis
- Not studied; no dose in label. Specialist input. Metabolites accumulate in kidney impairment; risk of prolonged hypoglycemia (label 8.6, 12.3).
- CRRT
- No data. Specialist input; insulin usually preferred in acute illness.
- Dialyzable? Not stated; unlikely (protein binding over 99.5%; label).
- Monitoring Blood glucose (hypoglycemia, which can be prolonged), hemoglobin A1c, kidney function. Hold in acute illness with poor intake.
Children (kidney dosing)
- eGFR ≥60
- Not approved for children; kidney dosing not applicable.
- eGFR 30–59
- Not approved for children; kidney dosing not applicable.
- eGFR 15–29
- Not approved for children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not approved for children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not approved for children; kidney dosing not applicable.
- Peritoneal dialysis
- Not approved for children; kidney dosing not applicable.
- CRRT
- Not approved for children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
8.6 Renal Impairment To minimize the risk of hypoglycemia, the recommended starting dose of glimepiride is 1 mg daily for all patients with type 2 diabetes and renal impairment [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)]. A multiple-dose titration study was conducted in 16 patients with type 2 diabetes and renal impairment using doses ranging from 1 mg to 8 mg daily for 3 months.
Baseline creatinine clearance ranged from 10 to 60 mL/min. The pharmacokinetics of glimepiride were evaluated in the multiple-dose titration study and the results were consistent with those observed in patients enrolled in a single-dose study. In both studies, the relative total clearance of glimepiride increased when kidney function was impaired.
Both studies also demonstrated that the elimination of the two major metabolites was reduced in patients with renal impairment [see Clinical Pharmacology (12.3)].
Dosing: Pediatric
- Approved ages
- Not recommended in pediatric patients (adverse effects on weight and hypoglycemia; label 8.4).
- Usual dose
- Not recommended.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use The pharmacokinetics, efficacy and safety of glimepiride have been evaluated in pediatric patients with type 2 diabetes as described below. Glimepiride is not recommended in pediatric patients because of its adverse effects on body weight and hypoglycemia. The pharmacokinetics of a 1 mg single dose of glimepiride was evaluated in 30 patients with type 2 diabetes (male = 7; female = 23) between ages 10 and 17 years.
The mean (± SD) AUC (0 to last) (339±203 ng
- hr/mL), C max (102±48 ng/mL) and t 1/2 (3.1±1.7 hours) for glimepiride were comparable to historical data from adults (AUC (0 to last) 315±96 ng
- hr/mL, C max 103±34 ng/mL, and t 1/2 5.3±4.1 hours). The safety and efficacy of glimepiride in pediatric patients was evaluated in a single-blind, 24-week trial that randomized 272 patients (8 to 17 years of age) with type 2 diabetes to glimepiride (n=135) or metformin (n=137). Both treatment-naive patients (those treated with only diet and exercise for at least 2 weeks prior to randomization) and previously treated patients (those previously treated or currently treated with other oral antidiabetic medications for at least 3 months) were eligible to participate. Patients who were receiving oral antidiabetic agents at the time of study entry discontinued these medications before randomization without a washout period. Glimepiride was initiated at 1 mg, and then titrated up to 2, 4, or 8 mg (mean last dose 4 mg) through Week 12, targeting a self-monitored fasting fingerstick blood glucose <126 mg/dL. Metformin was initiated at 500 mg twice daily and titrated at Week 12 up to 1000 mg twice daily (mean last dose 1365 mg). After 24 weeks, the overall mean treatment difference in HbA1c between glimepiride and metformin was 0.2%, favoring metformin (95% confidence interval -0.3% to +0.6%). Based on these results, the trial did not meet its primary objective of showing a similar reduction in HbA1c with glimepiride compared to metformin. Table 2: Change from Baseline in HbA1C and Body Weight in Pediatric Patients Taking Glimepiride or Metformin Metformin Glimepiride Treatment-Naive Patients * N=69 N=72 HbA1C (%) Baseline (mean) 8.2 8.3 Change from baseline (adjusted LS mean) + -1.2 -1.0 Adjusted Treatment Difference ‡ (95%CI) 0.2 (-0.3; 0.6) Previously Treated Patients * N=57 N=55 HbA1C (%) Baseline (mean) 9.0 8.7 Change from baseline (adjusted LS mean) + -0.2 0.2 Adjusted Treatment Difference ‡ (95%CI) 0.4 (-0.4; 1.2) Body Weight (kg) * N=126 N=129 Baseline (mean) 67.3 66.5 Change from baseline (adjusted LS mean) + 0.7 2.0 Adjusted Treatment Difference ‡ (95% CI) 1.3 (0.3; 2.3) * Intent-to-treat population using last-observation-carried-forward for missing data (glimepiride, n=127; metformin, n=126) + adjusted for baseline HbA 1c and Tanner Stage ‡ Difference is glimepiride – metformin with positive differences favoring metformin The profile of adverse reactions in pediatric patients treated with glimepiride was similar to that observed in adults [see Adverse Reactions (6)]. Hypoglycemic events documented by blood glucose values <36 mg/dL were observed in 4% of pediatric patients treated with glimepiride and in 1% of pediatric patients treated with metformin. One patient in each treatment group experienced a severe hypoglycemic episode (severity was determined by the investigator based on observed signs and symptoms).
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In clinical trials of glimepiride, 1053 of 3491 patients (30%) were >65 years of age. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. There were no significant differences in glimepiride pharmacokinetics between patients with type 2 diabetes ≤65 years (n=49) and those >65 years (n=42) [see Clinical Pharmacology (12.3)].
Glimepiride is substantially excreted by the kidney. Elderly patients are more likely to have renal impairment. In addition, hypoglycemia may be difficult to recognize in the elderly [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)]. Use caution when initiating glimepiride and increasing the dose of glimepiride in this patient population.
Dosage forms
Philippines
- Tablet: 1 mg, 2 mg, 3 mg, 4 mg
- Film-coated tablet: 1 mg, 2 mg
- Talet: 2 mg
Registered products in the Philippines
101 products registered with the Food and Drug Administration (FDA) Philippines list Glimepiride as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Glimeperide (1 product). Products registered under these spellings are included in the table and marked.
All registered products101
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AccemideGlimepiride | 2 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Accesspoint International Trading Inc. | DR-XY43149 | Feb 3, 2029 | |
AcotrilGlimepiride | 2 mg TabletFoil Strip x 10’s (Box of 100’s) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: PNSV ASIA CORPORATION | DR-XY34446 | Apr 9, 2028 | |
AmaraGlimepiride | 2 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Corbridge Group Phils., Inc.Importer: Ambica International Corporation | DRP-3348-01 | Nov 3, 2029 | |
AmaraGlimepiride | 2 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | ZIM LABORATORIES LTD.India | CORBRIDGE GROUP PHILS., INC.Importer: AMBICA INTERNATIONAL CORPORATIONTrader: RAINBOW LIFE SCIENCES PVT. LTD. | DRP-2488-01 | Jan 11, 2028 | |
Amara-4Glimepiride | 4 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Synmedic LaboratoriesIndia | Corbridge Group Phils., Inc.Importer: Ambica International Corporation | DRP-1693-01 | Oct 28, 2027 | |
AryaGlimepiride | 1 mg TabletFoil Strip x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: GX International, Inc. | DR-XY33171 | Apr 4, 2027 | |
AryaGlimepiride | 2 mg TabletFoil Strip x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: GX International, Inc. | DR-XY33173 | Apr 4, 2027 | |
AryaGlimepiride | 3 mg TabletFoil Strip x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: GX International, Inc. | DR-XY33172 | Apr 4, 2027 | |
AzulixGlimepiride | 2 mg TabletPVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DRP-2324 | Feb 15, 2031 | |
DiabeatsGlimepiride | 2 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's and 30's) | RxVAT-exempt | LifeSquare Laboratories, Inc.Philippines | — | DRP-4649 | Sep 6, 2031 | |
DiabeatsGLIMEPIRIDE | 3 mg tabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | LIFESQUARE LABORATORIES INCPhilippines | — | DRP-5170 | Feb 14, 2029 | |
DiabeatsGlimepiride | 4 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Lifesquare Laboratories Inc.Philippines | — | DRP-4813 | Feb 14, 2029 | |
DiabelifeGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's; Box of 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Pvt. Ltd.India | Life And Health Source Pharmaceutical Distribution Co.Importer: Medinova Pharmaceutical Inc. | DRP-12864-04 | Oct 18, 2027 | |
DiaglimGlimepiride | 2 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-1588 | Dec 19, 2028 | |
DiaglimGlimepiride | 3 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's Box of 30’s, 90’s and 100's | RxVAT-exempt | Lek S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-1587 | Dec 19, 2028 | |
DiamerideGlimepiride | 2 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Phil Pharmawealth, Inc. | DRP-7983 | Apr 26, 2027 | |
DianovGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's (Box of 10 Blister Packs x 10 Tablets) | RxVAT-exempt | Ratnamani Healthacare Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-12864 | Oct 18, 2027 | |
GenoffGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3019-02 | Sep 19, 2031 | |
GeoprideGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's Box of 20's | RxVAT-exempt | Geofman PharmaceuticalsPakistan | Sahar International Trading, Inc. | DRP-1893 | Feb 4, 2029 | |
GeoprideGlimepiride | 4 mg TabletAlu/PVC Blister Pack x 10's (Box of 20's); Alu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Geofman PharmaceuticalsPakistan | Sahar International Trading Inc. | DR-XY43230 | Feb 17, 2029 | |
GlimarexGlimepiride | 2 mg TaletAlu/Clear Pvc Blister Pack x 15's (Box of 120's) | RxVAT-exempt | Taiwan Biotech Co., Ltd.China | New Smart Formulae Trading Corp. | DR-XY35414 | Feb 9, 2031 | |
GlimarylGlimepiride | 2 mg TabletBlister Pack of 10's (Box of 30's) | RxVAT-exempt | HOVID BERHADMalaysia | HOVID INC. | DR-XY34393 | Mar 14, 2028 | |
Glime-M2Glimepiride | 2 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | ZIM LABORATORIES LTD.India | ARISTO PHARMA PHILIPPINES, INC.Importer: AMBICA INTERNATIONAL CORPORATIONTrader: RAINBOW LIFE SCIENCES PVT. LTD. | DRP-2488 | Jan 11, 2028 | |
Glime-M4Glimepiride | 4 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5548 | Oct 1, 2029 | |
GlimegenGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's (Box of 10 Blister Pack x 10 Tablets) | RxVAT-exempt | Ratnatris Pharmaceuticals Pvt. Ltd.India | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-12864-02 | Oct 18, 2027 | |
GlimepGlimepiride | 2 mg TabletPVC-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Flamingo Pharmaceuticals Ltd.India | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-4422-01 | Nov 23, 2031 | |
Glimesaph T2Glimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's Box of 30's | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-4152 | Dec 18, 2027 | |
Glimesaph T3Glimepiride | 3 mg TabletAlu/PVC Blister Pack of 10's (Box of 30's & 100's) | RxVAT-exempt | Sai Parenterals LimitedIndia | Nelpa Lifesciences Inc. | DRP-4151 | Sep 9, 2030 | |
Glimesaph T4Glimepiride | 4 mg TabletAlu/Alu Blister Pack of 10's (Box of 30's & 100's) | RxVAT-exempt | Sai Parenterals LimitedIndia | Nelpa Lifesciences Inc. | DRP-4101 | Sep 19, 2030 | |
GLIMESAPH-GE2Glimepiride | 2 mg TabletAlu/Pvc Blister Pack X 10'S (Box of 30's and 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-19040 | Oct 21, 2031 | |
Glimesaph-GE4Glimepiride | 4 mg TabletAlu/Alu Blister Pack of 10’s (Box of 30's and 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-19026 | Oct 19, 2031 | |
GlimesynGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Bell-Kenz Pharma Inc. | DRP-1165 | Oct 15, 2028 | |
GlimesynGlimepiride | 3 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Bell-Kenz Pharma Inc. | DRP-1167 | Oct 15, 2028 | |
Glimetil-1Glimepiride | 1 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hiral Labs LimitedIndia | Aglobal Care, Inc. | DRP-13335 | Feb 2, 2028 | |
Glimetil-2Glimepiride | 2 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hiral Labs LimitedIndia | Aglobal Care, Inc. | DRP-13334 | Feb 2, 2028 | |
GLIMORED 4Glimepiride | 4 mg TabletAlu/Alu Blister pack of 10’s (Box of 30’s); Alu/Alu Blister pack of 10’s (Box of 100’s) | RxVAT-exempt | Sai Parenterals LtdTSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India. | 777 RED PHARMA INC.Importer: Nelpa Lifesciences, Inc. | DRP-4101-02 | Sep 19, 2030 | |
GlimphageGlimepiride | 1 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-17232 | Oct 23, 2030 | |
4 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Amb Hk Enterprises Inc. | DRP-16420 | Mar 10, 2030 | ||
GlimphageGlimepiride | 4mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprise Inc.Importer: AMB HK Enterprises Inc. | DRP-13846 | May 15, 2028 | |
GlimproGlimepiride | 2 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | LifeSquare Laboratories, Inc.Philippines | Bewell Nutraceuticals Corp. | DRP-4649-02 | Jul 16, 2031 | |
GLIMPROGLIMEPIRIDE | 3 mg TabletAlu/ Clear PVC Blister Pack x 10’s (Box of 100's) | RxVAT-exempt | LIFESQUARE LABORATORIES INCPhilippines | BEWELL NUTRACEUTICALS CORP. | DRP-5170-02 | Feb 14, 2029 | |
GLIMPROGLIMEPIRIDE | 4 mg TabletAlu/Clear PVC Blister Pack x 10’s Box of 100's | RxVAT-exempt | LIFESQUARE LABORATORIES INCPhilippines | BEWELL NUTRACEUTICALS CORP. | DRP-4813-02 | Feb 14, 2029 | |
Glimryl-1Glimepiride | 1 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambica International Corporation | DRP-6709 | May 31, 2031 | |
Glimryl-2Glimepiride | 2 mg TabletAlu/Clear PVC Blister Pack of 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambica International Corporation | DRP-3019 | Sep 29, 2030 | |
Glimryl-3Glimepiride | 3 mg TabletAlu/Clear PVC Blister Pack of 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | TGP Pharma, Inc.Importer: Ambica International Corporation | DRP-6710 | May 31, 2031 | |
GlipedGlimepiride | 3 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's); Alu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | LifeSquare Laboratories Inc.Philippines | Novomed Inc. | DRP-5170-03 | Feb 14, 2029 | |
GlipedGlimepiride | 4 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Lifesquare Laboratories Inc.Philippines | Novomed Inc. | DRP-4813-03 | Feb 14, 2029 | |
GliperideGlimepiride | 2 mg TabletStrip Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Trader: Medhaus Pharma, Incorporated | DR-XY31781 | May 23, 2031 | |
GlirideGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | 777 Red Pharma IncImporter: Nelpa Lifesciences, Inc. | DRP-4152-01 | Dec 18, 2027 | |
Gliride 3Glimepiride | 3 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-4151-01 | Dec 18, 2027 | |
Gliride 4Glimepiride | 4 mg TabletAlu/Alu Blister Pack x 10's (Box of 28's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-4101-01 | Nov 19, 2027 | |
GlivaridGlimepiride | 2 mg TabletAluminum/PVDC Blister Pack x 10's (Box of 40's) | RxVAT-exempt | The ACME Laboratories Ltd.Bangladesh | Euro Generics International Phils., Inc. | DRP-6297 | Jul 4, 2031 | |
GlymaxGlimepiride | 2mg TabletAlu-PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | OxpharmImporter: AMB HK Enterprises Inc. | DRP-13848 | Jun 6, 2028 | |
GlymaxGlimepiride | 3mg TabletAlu-PVC blister pack. | RxVAT-exempt | Globela Pharma Private LimitedIndia | OxpharmImporter: AMB HK Enterprises Inc. | DRP-13847 | Jun 6, 2028 | |
GlyperGlimepiride | 2 mg TabletAlu-PVC Blister Pack x 10's (Box of 20's) | RxVAT-exempt | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | Ambica International Corporation | DRP-2947 | Feb 8, 2032 | |
GlyperGlimepiride | 4 mg TabletAlu/PVC Blister Pack x 10's (Box of 20's) | RxVAT-exempt | Maple Pharmaceuticals (Pvt.) Ltd.Pakistan | Ambica International Corporation | DRP-4255 | Apr 11, 2028 | |
GlypostadGlimepiride | 2 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lek S.A.Poland | STADA Philippines Inc.Importer: Sandoz Philippines Corporation | DRP-1588-04 | Dec 19, 2028 | |
GlypostadGlimepiride | 3 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lek S.A.Poland | STADA Philippines Inc.Importer: Sandoz Philippines Corporation | DRP-1587-04 | Dec 19, 2028 | |
GlyprideGlimepiride | 2 mg TabletAlu-PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-13848-01 | Jun 6, 2028 | |
GlyprideGlimepiride | 3 mg TabletAlu-PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-13847-01 | Jun 6, 2028 | |
GoperideGlimepiride | 2 mg TabletAlu-PVC Blister Pack x 10's (Box of 10 Blister Packs x 10 Tablets) | RxVAT-exempt | Ratnatris Pharmaceuticals Pvt. Ltd.India | Go Health Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc. | DRP-12864-01 | Oct 18, 2027 | |
LimglimGlimepiride | 2 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-14126 | Jun 23, 2028 | |
NoneGlimepiride | 1 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Ritemed Phils., Inc.Trader: UNILAB, Inc. | DRP-10056-01 | Jul 9, 2027 | |
NoneGlimepiride | 2 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-14126-01 | Jun 23, 2028 | |
NoneGlimepiride | 2 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Rose Pharmacy, IncorporatedImporter: Ambica International Corporation | DRP-14126-02 | Jun 23, 2028 | |
NoneGlimepiride | 2 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Watsons Personal Care Stores (Philippines), Inc.Trader: Gold Life Distribution Phils. Inc. | DRP-6981 | Oct 27, 2027 | |
NoneGlimepiride | 2 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Watsons Personal Care Stores (Philippines), Inc.Trader: Gold Life Distribution Phils. Inc. | DRP-6981-01 | Oct 27, 2027 | |
NoneGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Actimed, Inc. | DRP-1165-03 | Oct 15, 2028 | |
NoneGlimepiride | 2 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Ritemed Phils., Inc.Trader: UNILAB, Inc. | DRP-12276-01 | Jul 9, 2027 | |
NoneGlimepiride | 2 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 30's, 90's, and 100's) | RxVAT-exempt | Lek S.A.Poland | Ritemed Phils., Inc.Importer: Sandoz Philippines Corporation | DRP-1588-02 | Dec 19, 2028 | |
NoneGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-4152-02 | Dec 18, 2027 | |
NoneGlimepiride | 3 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Ritemed Phils., Inc.Trader: UNILAB, Inc. | DRP-10041-01 | Jul 9, 2027 | |
NoneGlimepiride | 3 mg TabletBlister Pack x 10’s Box of 100’s | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DRP-2270 | Dec 2, 2029 | |
NoneGlimepiride | 3mg TabletAlu Foil/Clear PVC Blister pack x 20's (Box of 20's and 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5668 | May 14, 2027 | |
NoneGlimepiride | 4 mg TabletAlu/PVC Blister Pack x 10's (Box of 20's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-1412 | Sep 25, 2028 | |
NoneGlimepiride | 4 mg TabletAlu/PVC Blister Pack x 10's (Box of 20's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-1412-01 | Sep 25, 2028 | |
NoneGlimepiride | 4 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Synmedic LaboratoriesIndia | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-1693-02 | Oct 28, 2027 | |
NoneGlimepiride | 4 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Diafarm Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-5548-01 | Oct 1, 2029 | |
NorizecGlimepiride | 1 mg TabletAlu/Clear PVC Blister Pack x 10's Box of 60's | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-10056 | Jul 9, 2027 | |
NorizecGlimepiride | 1 mg TabletAlu/PVC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | PT Darya-Varia Laboratoria TBKIndonesia | UNILAB, Inc. | DRP-13402 | Feb 14, 2028 | |
NorizecGlimepiride | 2 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: Unilab, Inc. | DRP-12276 | Jul 9, 2027 | |
NorizecGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | PT Darya-Varia Laboratoria TBKIndonesia | UNILAB, Inc. | DRP-13403 | Feb 14, 2028 | |
NORIZECGlimepiride | 3 mg TabletAlu/Clear PVC Blister Pack x 10's Box of 60's | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DRP-10041 | Jul 9, 2027 | |
NorizecGlimepiride | 3 mg TabletAlu/PVC Blister Pack x 10's (Box of 60's) | RxVAT-exempt | PT Darya-Varia Laboratoria TBKIndonesia | UNILAB, Inc. | DRP-13404 | Feb 14, 2028 | |
NovaglimGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Acme Formulation Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-13461 | Feb 23, 2028 | |
Pasglim 2Glimepiride | 2 mg TabletPVC-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-4422 | Nov 23, 2031 | |
Perglim 2Glimepiride | 2 mg TabletAlu/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd. | DR-XY37155 | Dec 3, 2029 | |
Perglim 4Glimepiride | 4 mg tabletAlu/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd. | DR-XY44124 | Feb 2, 2030 | |
RetaglimGlimepiride | 2 mg TabletAlu/PVC Blister Pack x 10's (Box of 10 Blister Packs x 10 Tablets) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-12864-03 | Oct 18, 2027 | |
RimeprilGlimepiride | 2 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | TGP Pharma Inc.Importer: Sandoz Philippines Corporation | DRP-1588-01 | Dec 19, 2028 | |
RimeprilGlimepiride | 3 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's Box of 30's, 90's, and 100's | RxVAT-exempt | Lek S.A.Poland | TGP Pharma Inc.Importer: Sandoz Philippines Corporation | DRP-1587-01 | Dec 19, 2028 | |
SoladinGlimepiride | 2 mg TabletBlister Pack x 10's (Box of 30's) | RxVAT-exempt | Sydenham Laboratories, Inc.Cavite | Trader: Medchoice Endocrine Group, Inc. | DRP-10964 | Jul 2, 2031 | |
SolosaGlimepiride | 1 mg TabletClear PVC/ Aluminum Foil Blister Strip x 30's (Box of 30's) | RxVAT-exempt | Sanofi S.r.l.Italy | Importer: sanofi-aventis Philippines Inc. | DRP-006 | Oct 8, 2029 | |
SolosaGlimepiride | 2mg TabletAlu Clear PVC blister pack by 15's (Box of 30's) | RxVAT-exempt | Sanofi S.p.A.Italy | Importer: sanofi-aventis Philippines, Inc. | DRP-007 | Jun 23, 2027 | |
SolosaGlimepiride | 3 mg TabletAlu/Clear PVC Blister Pack x 15's Box of 30's, 90's & 120's | RxVAT-exempt | Sanofi S.P.A.Italy | Importer: Sanofi-Aventis Philippines, Inc. | DRP-008 | Oct 8, 2027 | |
Sulfast 3Glimepiride | 3 mg TabletStrip Foil x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DR-XY30434 | Dec 23, 2029 | |
Syngly-4Glimepiride | 4 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Synmedic LaboratoriesIndia | Ambica International Corporation | DRP-1693 | Oct 28, 2027 | |
Trimep-2Glimepiride | 2 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-3348 | Nov 3, 2029 | |
UnbrandedGlimepiride | 2 mg TabletAluminum/PVDC Blister Pack x 10's (Box of 40's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | TGP Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-6297-02 | Jul 4, 2031 | |
VelacomGlimepiride | 2 mg TabletAluminum foil strip x 10's (Box of 30's) | RxVAT-exempt | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY49336 | Feb 18, 2030 | |
VelacomGlimepiride | 3 mg TabletAluminum foil strip x 10's (Box of 30's) | RxVAT-exempt | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY49335 | Feb 18, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Glimepiride is formulated as tablets of: 3 mg (Pale yellow colored, flat capsule shaped uncoated tablets having break line on both faces and GM and 3 engraved on either side of break line on one face.) Tablets (scored): 3 mg (3)
Warnings/Precautions
- Hypoglycemia: May be severe. Ensure proper patient selection, dosing, and instructions, particularly in at-risk populations (e.g., elderly, renally impaired) and when used with other anti-diabetic medications (5.1). Hypersensitivity Reactions: Postmarketing reports include anaphylaxis, angioedema and Stevens-Johnson Syndrome. If a reaction is suspected, promptly discontinue glimepiride, assess for other potential causes for the reaction, and institute alternative treatment for diabetes. (5.2)
- Hemolytic Anemia: Can occur if glucose 6-phosphate dehydrogenase (G6PD) deficient. Consider a non-sulfonylurea alternative. (5.3)
- Potential Increased Risk of Cardiovascular Mortality with Sulfonylureas: Inform patient of risks, benefits and treatment alternatives. (5.4)
- Macrovascular Outcomes: No clinical studies establishing conclusive evidence of macrovascular risk reduction with glimepiride or any other anti-diabetic drug (5.5).
5.1 Hypoglycemia
5.1 Hypoglycemia All sulfonylureas, including glimepiride, can cause severe hypoglycemia [see Adverse Reactions (6.1)]. The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. These impairments may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.
Severe hypoglycemia can lead to unconsciousness or convulsions and may result in temporary or permanent impairment of brain function or death. Patients must be educated to recognize and manage hypoglycemia. Use caution when initiating and increasing glimepiride doses in patients who may be predisposed to hypoglycemia (e.g., the elderly, patients with renal impairment, patients on other anti-diabetic medications).
Debilitated or malnourished patients, and those with adrenal, pituitary, or hepatic impairment are particularly susceptible to the hypoglycemic action of glucose-lowering medications. Hypoglycemia is also more likely to occur when caloric intake is deficient, after severe or prolonged exercise, or when alcohol is ingested.
Early warning symptoms of hypoglycemia may be different or less pronounced in patients with autonomic neuropathy, the elderly, and in patients who are taking beta-adrenergic blocking medications or other sympatholytic agents. These situations may result in severe hypoglycemia before the patient is aware of the hypoglycemia.
5.2 Hypersensitivity Reactions
5.2 Hypersensitivity Reactions There have been postmarketing reports of hypersensitivity reactions in patients treated with glimepiride, including serious reactions such as anaphylaxis, angioedema, and Stevens-Johnson Syndrome [see Adverse Reactions (6.2)]. If a hypersensitivity reaction is suspected, promptly discontinue glimepiride, assess for other potential causes for the reaction, and institute alternative treatment for diabetes.
5.3 Hemolytic Anemia
5.3 Hemolytic Anemia Sulfonylureas can cause hemolytic anemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. Because glimepiride is a sulfonylurea, use caution in patients with G6PD deficiency and consider the use of a non-sulfonylurea alternative. There are also postmarketing reports of hemolytic anemia in patients receiving glimepiride who did not have known G6PD deficiency [see Adverse Reactions (6.2)].
5.4 Increased Risk of Cardiovascular Mortality with Sulfonylureas
5.4 Increased Risk of Cardiovascular Mortality with Sulfonylureas The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term, prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes.
The study involved 823 patients who were randomly assigned to one of four treatment groups. UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2 and a half times that of patients treated with diet alone.
A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning.
The patient should be informed of the potential risks and advantages of glimepiride and of alternative modes of therapy. Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.
5.5 Macrovascular Outcomes
5.5 Macrovascular Outcomes There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with glimepiride or any other anti-diabetic drug.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Drugs that raise hypoglycemia risk (insulin, other antidiabetics, ACE inhibitors, quinolones, clarithromycin, fluconazole, NSAIDs, sulfonamides) | Adjust or monitor | More hypoglycemia (label 7.1); beta-blockers can mask it. | Monitor glucose; consider lower glimepiride dose. |
| Oral miconazole | Avoid | Severe hypoglycemia (label 7.2). | Avoid the combination. |
| Colesevelam | Minor | Less glimepiride absorption (label). | Give glimepiride at least 4 hours before colesevelam. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewed- Certain medications may affect glucose metabolism, requiring glimepiride dose adjustment and close monitoring of blood glucose. (7.1)
- Miconazole: Severe hypoglycemia can occur when glimepiride and oral miconazole are used concomitantly. (7.2)
- Cytochrome P450 2C9 interactions: Inhibitors and inducers of cytochrome P450 2C9 may affect glycemic control by altering glimepiride plasma concentrations. (7.3)
- Colesevelam: Coadministration may reduce glimepiride absorption. Glimepiride should be administered at least 4 hours prior to colesevelam. (2.1, 7.4)
7.1 Drugs Affecting Glucose Metabolism
7.1 Drugs Affecting Glucose Metabolism A number of medications affect glucose metabolism and may require glimepiride dose adjustment and particularly close monitoring for hypoglycemia or worsening glycemic control. The following are examples of medications that may increase the glucose-lowering effect of sulfonylureas including glimepiride, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors.
When these medications are administered to a patient receiving glimepiride, monitor the patient closely for hypoglycemia. When these medications are withdrawn from a patient receiving glimepiride, monitor the patient closely for worsening glycemic control. The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid.
When these medications are administered to a patient receiving glimepiride, monitor the patient closely for worsening glycemic control. When these medications are withdrawn from a patient receiving glimepiride, monitor the patient closely for hypoglycemia. Beta-blockers, clonidine, and reserpine may lead to either potentiation or weakening of glimepiride’s glucose-lowering effect.
Both acute and chronic alcohol intake may potentiate or weaken the glucose-lowering action of glimepiride in an unpredictable fashion. The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine.
7.2 Miconazole
7.2 Miconazole A potential interaction between oral miconazole and sulfonylureas leading to severe hypoglycemia has been reported. Whether this interaction also occurs with other dosage forms of miconazole is not known.
7.3 Cytochrome P450 2
7.3 Cytochrome P450 2C9 Interactions There may be an interaction between glimepiride and inhibitors (e.g., fluconazole) and inducers (e.g., rifampin) of cytochrome P450 2C9. Fluconazole may inhibit the metabolism of glimepiride, causing increased plasma concentrations of glimepiride which may lead to hypoglycemia. Rifampin may induce the metabolism of glimepiride, causing decreased plasma concentrations of glimepiride which may lead to worsening glycemic control.
7.4 Concomitant Administration of Colesevelam
7.4 Concomitant Administration of Colesevelam Colesevelam can reduce the maximum plasma concentration and total exposure of glimepiride when the two are coadministered. However, absorption is not reduced when glimepiride is administered 4 hours prior to colesevelam. Therefore, glimepiride should be administered at least 4 hours prior to colesevelam.
Adverse reactions
Common
- Hypoglycemia
- Dizziness, asthenia, headache, nausea
Serious
- Severe or prolonged hypoglycemia
- Hypersensitivity (anaphylaxis, angioedema, Stevens-Johnson syndrome)
- Hemolytic anemia in G6PD deficiency
- Possible increased cardiovascular mortality (sulfonylurea class warning)
The following serious adverse reactions are discussed in more detail below and elsewhere in the labeling: Hypoglycemia [see Warnings and Precautions (5.1)] Hemolytic anemia [see Warnings and Precautions (5.3)] Common adverse reactions in clinical trials (≥5% and more common than with placebo) include hypoglycemia, headache, nausea, and dizziness (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Micro Labs USA, Inc. at 1-855-839-8195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Approximately 2,800 patients with type 2 diabetes have been treated with glimepiride in the controlled clinical trials.
In these trials, approximately 1,700 patients were treated with glimepiride for at least 1 year. In clinical trials, the most common adverse reactions with glimepiride were hypoglycemia, dizziness, asthenia, headache, and nausea. Table 1 summarizes adverse events, other than hypoglycemia, that were reported in 11 pooled placebo-controlled trials, whether or not considered to be possibly or probably related to study medication.
Treatment duration ranged from 13 weeks to 12 months. Terms that are reported represent those that occurred at an incidence of ≥5% among glimepiride-treated patients and more commonly than in patients who received placebo. Table 1: Eleven Pooled Placebo-Controlled Trials ranging from 13 weeks to 12 months: Adverse Events (excluding hypoglycemia) Occurring in ≥5% of Glimepiride-treated Patients and at a Greater Incidence than with Placebo * Glimepiride N=745 % Placebo N=294 % Headache 8.2 7.8 Accidental Injury † 5.8 3.4 Flu Syndrome 5.4 4.4 Nausea 5.0 3.4 Dizziness 5.0 2.4 * Glimepiride doses ranged from 1 to 16 mg administered daily † Insufficient information to determine whether any of the accidental injury events were associated with hypoglycemia Hypoglycemia In a randomized, double-blind, placebo-controlled monotherapy trial of 14 weeks duration, patients already on sulfonylurea therapy underwent a 3-week washout period then were randomized to glimepiride 1 mg, 4 mg, 8 mg, or placebo.
Patients randomized to glimepiride 4 mg or 8 mg underwent forced-titration from an initial dose of 1 mg to these final doses, as tolerated [see Clinical Studies (14.1)]. The overall incidence of possible hypoglycemia (defined by the presence of at least one symptom that the investigator believed might be related to hypoglycemia; a concurrent glucose measurement was not required) was 4% for glimepiride 1 mg, 17% for glimepiride 4 mg, 16% for glimepiride 8 mg and 0% for placebo.
All of these events were self-treated. In a randomized, double-blind, placebo-controlled monotherapy trial of 22 weeks duration, patients received a starting dose of either 1 mg glimepiride or placebo daily. The dose of glimepiride was titrated to a target fasting plasma glucose of 90 to 150 mg/dL. Final daily doses of glimepiride were 1, 2, 3, 4, 6, or 8 mg [see Clinical Studies (14.1)].
The overall incidence of possible hypoglycemia (as defined above for the 14-week trial) for glimepiride vs. placebo was 19.7% vs. 3.2%. All of these events were self-treated. Weight gain Glimepiride, like all sulfonylureas, can cause weight gain [see Clinical Studies (14.1)]. Allergic Reactions In clinical trials, allergic reactions, such as pruritus, erythema, urticaria, and morbilliform or maculopapular eruptions, occurred in less than 1% of glimepiride-treated patients.
These may resolve despite continued treatment with glimepiride. There are postmarketing reports of more serious allergic reactions (e.g., dyspnea, hypotension, shock) [see Warnings and Precautions (5.2)]. Laboratory Tests Elevated serum alanine aminotransferase (ALT) In 11 pooled placebo-controlled trials of glimepiride, 1.9% of glimepiride-treated patients and 0.8% of placebo-treated patients developed serum ALT greater than 2 times the upper limit of the reference range.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of glimepiride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Serious hypersensitivity reactions, including anaphylaxis, angioedema, and Stevens-Johnson Syndrome [see Warnings and Precautions (5.2)] Hemolytic anemia in patients with and without G6PD deficiency [see Warnings and Precautions (5.3)] Impairment of liver function (e.g., with cholestasis and jaundice), as well as hepatitis, which may progress to liver failure Porphyria cutanea tarda, photosensitivity reactions and allergic vasculitis Leukopenia, agranulocytosis, aplastic anemia, and pancytopenia Thrombocytopenia (including severe cases with platelet count less than 10,000/μL) and thrombocytopenic purpura Hepatic porphyria reactions and disulfiram-like reactions Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH), most often in patients who are on other medications or who have medical conditions known to cause hyponatremia or increase release of antidiuretic hormone Dysgeusia Alopecia
Adverse reaction frequency tables (US label) US FDA label
| Table 1: Eleven Pooled Placebo-Controlled Trials ranging from 13 weeks to 12 months: Adverse Events (excluding hypoglycemia) Occurring in ≥5% of Glimepiride-treated Patients and at a Greater Incidence than with Placebo * | ||
| Glimepiride N=745 % | Placebo N=294 % | |
| Headache | 8.2 | 7.8 |
| Accidental Injury † | 5.8 | 3.4 |
| Flu Syndrome | 5.4 | 4.4 |
| Nausea | 5.0 | 3.4 |
| Dizziness | 5.0 | 2.4 |
| *Glimepiride doses ranged from 1 to 16 mg administered daily † Insufficient information to determine whether any of the accidental injury events were associated with hypoglycemia | ||
Monitoring parameters
- Blood glucose (hypoglycemia, which can be prolonged), hemoglobin A1c, kidney function. Hold in acute illness with poor intake. Kidney
- Blood glucose and hemoglobin A1c
- Kidney function
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from a small number of published studies and postmarketing experience with glimepiride use in pregnancy over decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal outcomes. However, sulfonylureas (including glimepiride) cross the placenta and have been associated with neonatal adverse reactions such as hypoglycemia.
Therefore, glimepiride should be discontinued at least two weeks before expected delivery (see Clinical Considerations). Poorly controlled diabetes in pregnancy is also associated with risks to the mother and fetus (see Clinical Considerations). In animal studies (see Data), there were no effects on embryo-fetal development following administration of glimepiride to pregnant rats and rabbits at oral doses approximately 4000 times and 60 times the maximum human dose based on body surface area, respectively.
However, fetotoxicity was observed in rats and rabbits at doses 50 times and 0.1 times the maximum human dose, respectively. The estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes with a HbA1c >7% and has been reported to be as high as 20% to 25% in women with a HbA1c >10%.
The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo-fetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications.
Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia-related morbidity. Fetal/neonatal adverse reactions Neonates of women with gestational diabetes who are treated with sulfonylureas during pregnancy may be at increased risk for neonatal intensive care admission and may develop respiratory distress, hypoglycemia, birth injury, and be large for gestational age.
Prolonged severe hypoglycemia, lasting 4 to 10 days, has been reported in neonates born to mothers receiving a sulfonylurea at the time of delivery and has been reported with the use of agents with a prolonged half-life. Observe newborns for symptoms of hypoglycemia and respiratory distress and manage accordingly. Dose adjustments during pregnancy and the postpartum period Due to reports of prolonged severe hypoglycemia in neonates born to mothers receiving a sulfonylurea at the time of delivery, glimepiride should be discontinued at least two weeks before expected delivery (see Fetal/Neonatal Adverse Reactions).
Data Animal data In animal studies, there was no increase in congenital anomalies, but an increase in fetal deaths occurred in rats and rabbits at glimepiride doses 50 times (rats) and 0.1 times (rabbits) the maximum recommended human dose (based on body surface area). This fetotoxicity was observed only at doses inducing maternal hypoglycemia and is believed to be directly related to the pharmacologic (hypoglycemic) action of glimepiride, as has been similarly noted with other sulfonylureas.
Mechanism of action
12.1 Mechanism of Action Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta cells. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics In healthy subjects, the time to reach maximal effect (minimum blood glucose concentrations) was approximately 2 to 3 hours after single oral doses of glimepiride. The effects of glimepiride on HbA 1c, fasting plasma glucose, and postprandial glucose have been assessed in clinical trials [see Clinical Studies (14)].
Pharmacokinetics
Key PK parameters
| Time to peak | 2 to 3 hours |
|---|---|
| Half-life in kidney failure (ESKD) kidney | Parent unchanged; M1 and M2 half-lives rise as kidney function falls (label) |
| Volume of distribution | 8.8 L |
| Protein binding | Over 99.5% |
| Metabolism (CYP, transporters) | Hepatic CYP2C9 to M1, then M2 |
| Active metabolites | M1 (about one-third of parent activity in animals) |
| Renal excretion kidney | About 60% of radioactivity in urine (as M1 and M2; no parent drug) |
| Dialyzability kidney | Not stated |
Excretion When 14 C-glimepiride was given orally to 3 healthy male subjects, approximately 60% of the total radioactivity was recovered in the urine in 7 days.
After intravenous dosing in patients, no significant biliary excretion of glimepiride or its M1 metabolite was observed.
The apparent terminal half-life (T 1/2 ) for glimepiride did not change, while the half-lives for M1 and M2 increased as renal function decreased.
Mean urinary excretion of M1 plus M2 as a percentage of dose decreased from 44.4% for Group I to 21.9% for Group II and 9.3% for Group III.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption Studies with single oral doses of glimepiride in healthy subjects and with multiple oral doses in patients with type 2 diabetes showed peak drug concentrations (C max) 2 to 3 hours postdose. When glimepiride was given with meals, the mean C max and AUC (area under the curve) were decreased by 8% and 9%, respectively.
Glimepiride does not accumulate in serum following multiple dosing. The pharmacokinetics of glimepiride does not differ between healthy subjects and patients with type 2 diabetes. Clearance of glimepiride after oral administration does not change over the 1 mg to 8 mg dose range, indicating linear pharmacokinetics. In healthy subjects, the intraindividual and interindividual variabilities of glimepiride pharmacokinetic parameters were 15% to 23% and 24% to 29%, respectively.
Distribution After intravenous dosing in healthy subjects, the volume of distribution (Vd) was 8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min. Protein binding was greater than 99.5%. Metabolism Glimepiride is completely metabolized by oxidative biotransformation after either an intravenous or oral dose.
The major metabolites are the cyclohexyl hydroxy methyl derivative (M1) and the carboxyl derivative (M2). Cytochrome P450 2C9 is involved in the biotransformation of glimepiride to M1. M1 is further metabolized to M2 by one or several cytosolic enzymes. M2 is inactive. In animals, M1 possesses about one-third of the pharmacological activity of glimepiride, but it is unclear whether M1 results in clinically meaningful effects on blood glucose in humans.
Excretion When 14 C-glimepiride was given orally to 3 healthy male subjects, approximately 60% of the total radioactivity was recovered in the urine in 7 days. M1 and M2 accounted for 80 to 90% of the radioactivity recovered in the urine. The ratio of M1 to M2 in the urine was approximately 3:2 in two subjects and 4:1 in one subject.
Approximately 40% of the total radioactivity was recovered in feces. M1 and M2 accounted for about 70% (ratio of M1 to M2 was 1:3) of the radioactivity recovered in feces. No parent drug was recovered from urine or feces. After intravenous dosing in patients, no significant biliary excretion of glimepiride or its M1 metabolite was observed.
Specific Populations Geriatric patients A comparison of glimepiride pharmacokinetics in patients with type 2 diabetes ≤65 years and those >65 years was evaluated in a multiple-dose study using glimepiride 6 mg daily. There were no significant differences in glimepiride pharmacokinetics between the two age groups. The mean AUC at steady state for the older patients was approximately 13% lower than that for the younger patients; the mean weight-adjusted clearance for the older patients was approximately 11% higher than that for the younger patients.
Gender There were no differences between males and females in the pharmacokinetics of glimepiride when adjustment was made for differences in body weight. Race No studies have been conducted to assess the effects of race on glimepiride pharmacokinetics but in placebo-controlled trials of glimepiride in patients with type 2 diabetes, the reduction in HbA 1C was comparable in Caucasians (n = 536), blacks (n = 63), and Hispanics (n = 63).
Renal impairment In a single-dose, open-label study, glimepiride 3 mg was administered to patients with mild, moderate and severe renal impairment as estimated by creatinine clearance (CLcr): Group I consisted of 5 patients with mild renal impairment (CLcr > 50 mL/min), Group II consisted of 3 patients with moderate renal impairment (CLcr = 20 to 50 mL/min) and Group III consisted of 7 patients with severe renal impairment (CLcr < 20 mL/min). Although glimepiride serum concentrations decreased with decreasing renal function, Group III had a 2.3-fold higher mean AUC for M1 and an 8.6-fold higher mean AUC for M2 compared to corresponding mean AUCs in Group I.
The apparent terminal half-life (T 1/2) for glimepiride did not change, while the half-lives for M1 and M2 increased as renal function decreased. Mean urinary excretion of M1 plus M2 as a percentage of dose decreased from 44.4% for Group I to 21.9% for Group II and 9.3% for Group III. Hepatic impairment It is unknown whether there is an effect of hepatic impairment on glimepiride pharmacokinetics because the pharmacokinetics of glimepiride has not been adequately evaluated in patients with hepatic impairment.
Obese Patient The pharmacokinetics of glimepiride and its metabolites were measured in a single-dose study involving 28 patients with type 2 diabetes who either had normal body weight or were morbidly obese. While the t max, clearance and volume of distribution of glimepiride in the morbidly obese patients were similar to those in the normal weight group, the morbidly obese had lower C max and AUC than those of normal body weight.
The mean C max, AUC 0 to 24, AUC 0 to ∞ values of glimepiride in normal vs. morbidly obese patients were 547 ± 218 ng/mL vs. 410 ± 124 ng/mL, 3210 ± 1030 hours·ng/mL vs. 2820 ± 1110 hours·ng/mL and 4000 ± 1320 hours·ng/mL vs. 3280 ± 1360 hours·ng/mL, respectively. Drug Interactions Aspirin In a randomized, double-blind, two-period, crossover study, healthy subjects were given either placebo or aspirin 1 gram three times daily for a total treatment period of 5 days.
On Day 4 of each study period, a single 1 mg dose of glimepiride was administered. The glimepiride doses were separated by a 14-day washout period. Co-administration of aspirin and glimepiride resulted in a 34% decrease in the mean glimepiride AUC and a 4% decrease in the mean glimepiride C max. Colesevelam Conconmitant administration of colesevelam and glimepiride resulted in reductions in glimepiride AUC 0 to ∞ and C max of 18% and 8%, respectively.
When glimepiride was administered 4 hours prior to colesevelam, there was no significant change in glimepiride AUC 0 to ∞ or C max, -6% and 3%, respectively [see Dosage and Administration (2.1) and Drug Interactions (7.4)]. Cimetidine and ranitidine In a randomized, open-label, 3-way crossover study, healthy subjects received either a single 4 mg dose of glimepiride alone, glimepiride with ranitidine (150 mg twice daily for 4 days; glimepiride was administered on Day 3), or glimepiride with cimetidine (800 mg daily for 4 days; glimepiride was administered on Day 3).
Coadministration of cimetidine or ranitidine with a single 4 mg oral dose of glimepiride did not significantly alter the absorption and disposition of glimepiride. Propranolol In a randomized, double-blind, two-period, crossover study, healthy subjects were given either placebo or propranolol 40 mg three times daily for a total treatment period of 5 days.
On Day 4 of each study period, a single 2 mg dose of glimepiride was administered. The glimepiride doses were separated by a 14-day washout period. Concomitant administration of propranolol and glimepiride significantly increased glimepiride C max, AUC, and T 1/2 by 23%, 22%, and 15%, respectively, and decreased glimepiride CL/f by 18%.
The recovery of M1 and M2 from urine was not changed. Warfarin In an open-label, two-way, crossover study, healthy subjects received 4 mg of glimepiride daily for 10 days. Single 25 mg doses of warfarin were administered 6 days before starting glimepiride and on Day 4 of glimepiride administration. The concomitant administration of glimepiride did not alter the pharmacokinetics of R- and S-warfarin enantiomers.
No changes were observed in warfarin plasma protein binding. Glimepiride resulted in a statistically significant decrease in the pharmacodynamic response to warfarin. The reductions in mean area under the prothrombin time (PT) curve and maximum PT values during glimepiride treatment were 3.3% and 9.9%, respectively, and are unlikely to be clinically relevant.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Glimepiride 3 mg · Lifsa Drugs LLC [US FDA-approved label, version 1, August 20, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51157849-7990-4a8b-ae50-eda1baf93cfa
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Lifsa Drugs LLC. (2024). Glimepiride tablets [Prescribing information; US FDA-approved label, ANDA091220, set ID 51157849-7990-4a8b-ae50-eda1baf93cfa, version effective August 20, 2024]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51157849-7990-4a8b-ae50-eda1baf93cfa
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .
